CoChat
Sign Up
Cited by 5Neuroendocrine Tumor Research AdvancesPancreatic function and diabetesPancreatic and Hepatic Oncology Research

Diagnosis and Management of Benign Secreting Pancreatic Insulinoma: What’s New? 4 Case Report

Open access
Bahou, Khawla, Achour, Youssef, Ilahiane, Mehdi, Sekkat, Hamza, Bakali, Younes, Mhamdi Alaoui, Mouna, Raiss, Mohammed, Sabbah, Farid +1 more·2025·Rare Tumors
DOI 10.1177/20363613241313409PMC PMC11713962
Open this paper in CoChat — free account

Abstract

Introduction and importance: Even though insulinoma is the most frequent neuroendocrine tumor, it represents only 2% of pancreatic 2% of all pancreatic neoplasms. Diagnosis is relatively simple, and surgery after accurate determination of the tumors location within the pancreas is the cornerstone of its treatment. Case presentation: We herein report 4 patients undergoing various surgeries for benign secreting insulinomas, after extensive radiological and endoscopic exploration. Clinical discussion: Diagnosis is relatively simple relying on clinical and biological criteria, it must be followed by an extensive and accurate preoperative determination of the tumors localization. The laparoscopic tumoral enucleation is the treatment of choice for small isolated tumors, but open surgery still has its indications. Conclusion: Pancreatic insulinoma is a rare neuroendocrine tumor that can be life-threatening due to hypoglycemic manifestations. The diagnosis is based on clinical and biological criteria. echo endoscopy and to a lesser extent radiological exploration can precisely determine the tumors location. Laparoscopic surgical enucleation of the tumor remains the preferred curative treatment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/20363613241313409

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Patients with insulinoma may report weight gain, as insulin has anabolic properties and inhibits lipolysis and glycogenolysis.

    “Patients may report weight gain, as insulin has anabolic properties and inhibits lipolysis and glycogenolysis [86].”

    From Non-Diabetic Hypoglycemia: Evaluation and Management in Adults (2025) · cites this paper as [86]

    The Clinical Presentation section (page unavailable) reports that all four patients with insulinoma reported weight gain, supporting the first part of the claim. The paper does not explain that weight gain through insulin’s anabolic properties or inhibition of lipolysis and glycogenolysis; the Discussion mentions glycogenolysis only in describing diazoxide treatment. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 50

  1. [1]Bégu-Le Corroller A Valéro R Moutardier V, et al. Aggressive multimodal therapy of sporadic malignant insulinoma can improve survival: a retrospective 35-year study of 12 patients. Diabetes Metab 2008; 34(4): 343– 348. DOI: 10.1016/j.diabet.2008.01.013. 18556231 · DOI
  2. [2]Ruiz E. Tratamiento quirúrgico del cáncer gástrico. Diagnostico 2021; 60(2): 98– 103.
  3. [3]Okabayashi T Shima Y Sumiyoshi T, et al. Diagnosis and management of insulinoma. World J Gastroenterol 2013; 19(6): 829– 837. DOI: 10.3748/wjg.v19.i6.829. 23430217 PMC3574879 · DOI · Paper page
  4. [4]Shin JJ Gorden P Libutti SK. Insulinoma: pathophysiology, localization and management. Future Oncol 2010; 6(2): 229– 237. DOI: 10.2217/fon.09.165. 20146582 PMC3498768 · DOI
  5. [6]Graves TD Gandhi S Smith SJM, et al. Misdiagnosis of seizures: insulinoma presenting as adult-onset seizure disorder. J Neurol Neurosurg Psychiatry 2004; 75(8): 1091– 1092. DOI: 10.1136/jnnp.2003.029249. 15258206 PMC1739168 · DOI
  6. [7]Service FJ McMahon MM O’Brien PC, et al. Functioning insulinoma—incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc 1991; 66(7): 711– 719. DOI: 10.1016/S0025-6196(12)62083-7. 1677058 · DOI · Paper page
  7. [8]Hadjkacem F Kalthoum M Ghorbel D, et al. [Insulinoma associated with adrenocorticotropic insufficiency and hypergonadotropic hypogonadism: a case study]. Pan Afr Med J 2019; 34: 32. DOI: 10.11604/pamj.2019.34.32.14865. 31762900 PMC6859031 · DOI
  8. [9]Fernández-Cruz L Herrera M Sáenz A, et al. Laparoscopic pancreatic surgery in patients with neuroendocrine tumours: indications and limits. Best Pract Res Clin Endocrinol Metabol 2001; 15(2): 161– 175. DOI: 10.1053/beem.2001.0133. 11472032 · DOI
  9. [10]Maggio I Mollica V Brighi N, et al. The functioning side of the pancreas: a review on insulinomas. J Endocrinol Invest 2020; 43(2): 139– 148. DOI: 10.1007/s40618-019-01091-w. 31368049 · DOI
  10. [11]Vanderveen K Grant C. Insulinoma. In: Sturgeon C (eds) Endocrine Neoplasia. Vol 153. Cancer Treatment and Research. Boston, MA: Springer US; 2010, pp. 235– 252. DOI: 10.1007/978-1-4419-0857-5_13. 19957228 · DOI
  11. [12]Matej A Bujwid H Wroński J. Glycemic control in patients with insulinoma. Hormones (Basel) 2017; 15(4): 489– 499. DOI: 10.14310/horm.2002.1706. 28222404 · DOI
  12. [13]Toaiari M Davì MV Dalle Carbonare L, et al. Presentation, diagnostic features and glucose handling in a monocentric series of insulinomas. J Endocrinol Invest 2013; 36: 753– 758. DOI: 10.3275/8942. 23608735 · DOI
  13. [14]Aggeli C Nixon AM Karoumpalis I, et al. Laparoscopic surgery for pancreatic insulinomas: an update. Hormones (Basel) 2016; 15(2): 157– 169. DOI: 10.14310/horm.2002.1670. 27376420 · DOI
  14. [15]Mathur A Gorden P Libutti SK. Insulinoma. Surgical Clinics 2009; 89(5): 1105– 1121. DOI: 10.1016/j.suc.2009.06.009. 19836487 PMC3470467 · DOI · Paper page
  15. [16]De Albuquerque Neto CC da Silva Lira N Albuquerque MARC, et al. Surgical resection of pancreatic insulinoma during pregnancy: case report and literature review. Int J Surg Case Rep 2019; 61: 119– 122. DOI: 10.1016/j.ijscr.2019.07.019. 31357102 PMC6664231 · DOI
  16. [17]Burghardt L Meier JJ Uhl W, et al. Importance of localization of insulinomas: a systematic analysis. J Hepatobiliary Pancreat Sci 2019; 26(9): 383– 392. DOI: 10.1002/jhbp.642. 31211879 · DOI
  17. [18]Fidler JL Fletcher JG Reading CC, et al. Preoperative detection of pancreatic insulinomas on multiphasic helical CT. AJR Am J Roentgenol 2003; 181(3): 775– 780. DOI: 10.2214/ajr.181.3.1810775. 12933480 · DOI
  18. [19]Antonakis PT Ashrafian H Martinez-Isla A. Pancreatic insulinomas: laparoscopic management. World J Gastrointest Endosc 2015; 7(16): 1197– 1207. DOI: 10.4253/wjge.v7.i16.1197. 26566426 PMC4639741 · DOI
  19. [20]Anderson MA Nostrant TT Scheiman JM. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Arch Surg 2000; 95(9): 1202. DOI: 10.1001/archsurg.142.12.1202. 11007228 · DOI
  20. [21]McLean AM Fairclough PD. Endoscopic ultrasound in the localisation of pancreatic islet cell tumours. Best Pract Res Clin Endocrinol Metabol 2005; 19(2): 177– 193. DOI: 10.1016/j.beem.2004.11.012. 15763694 · DOI · Paper page
  21. [22]Mabrut JY Lifante JC Cherki S, et al. La localisation préopératoire des insulinomes est-elle utile. Ann Chir 2001; 126(9): 850– 856. DOI: 10.1016/S0003-3944(01)00620-4. 11760575 · DOI
  22. [23]De Herder WW Niederle B Scoazec JY, et al. Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology 2006; 84(3): 183– 188. DOI: 10.1159/000098010. 17312378 · DOI
  23. [24]Kann PH Moll R Bartsch D, et al. Endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-FNA) in insulinomas: indications and clinical relevance in a single investigator cohort of 47 patients. Endocrine 2017; 56(1): 158– 163. DOI: 10.1007/s12020-016-1179-z. 27905047 · DOI
  24. [25]Luigiano C Ferrara F Morace C, et al. Endoscopic tattooing of gastrointestinal and pancreatic lesions. Adv Ther 2012; 29: 864– 873. DOI: 10.1007/s12325-012-0056-2. 23054693 · DOI
  25. [26]Placzkowski KA Vella A Thompson GB, et al. Secular trends in the presentation and management of functioning insulinoma at the mayo clinic, 1987–2007. J Clin Endocrinol Metab 2009; 94: 1069– 1073. DOI: 10.1210/jc.2008-2031. 19141587 · DOI · Paper page
  26. [27]Nockel P Babic B Millo C, et al. Localization of insulinoma using 68Ga-DOTATATE PET/CT scan. J Clin Endocrinol Metab 2017; 102(1): 195– 199. DOI: 10.1210/jc.2016-3445. 27805844 PMC6083884 · DOI
  27. [28]Anoun N Hasnaoui H Hassani FA, et al. [High grade insulinoma detected in a patient with a 5-year history of severe hypoglycemias]. Pan Afr Med J 2017; 27: 250. DOI: 10.11604/pamj.2017.27.250.13144. 28979651 PMC5622836 · DOI
  28. [29]Öberg K. Pancreatic endocrine tumors. Semin Oncol 2010; 37: 594– 618. DOI: 10.1053/j.seminoncol.2010.10.014. 21167379 · DOI
  29. [30]Guettier JM Gorden P. Insulin secretion and insulin-producing tumors. Expet Rev Endocrinol Metabol 2010; 5(2): 217– 227. DOI: 10.1586/eem.09.83. PMC2853964 20401170 · DOI
  30. [31]Brown E Watkin D Evans J, et al. Multidisciplinary management of refractory insulinomas. Clin Endocrinol 2018; 88(5): 615– 624. DOI: 10.1111/cen.13528. 29205458 · DOI
  31. [32]Hofland J Falconi M Christ E, et al. European neuroendocrine tumor society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes. J Neuroendocrinol 2023; 35(8): e13318. DOI: 10.1111/jne.13318. 37578384 · DOI
  32. [33]Sánchez-Bueno F Rodríguez González JM Torres Salmerón G, et al. Prognostic factors in resected pancreatic neuroendocrine tumours: experience in 95 patients. Cir Esp 2016; 94(8): 473– 480. DOI: 10.1016/j.ciresp.2016.05.010. 27450270 · DOI
  33. [34]Sekkat H Kada A El Hamzaoui J, et al. Middle segment pancreatectomy: does it deserve a second chance? Report of three cases and review of the literature. Int J Surg Case Rep 2023; 107: 108268. DOI: 10.1016/j.ijscr.2023.108268. 37187113 PMC10197007 · DOI
  34. [35]Dhar J Samanta J Nabi Z, et al. Endoscopic ultrasound-guided radiofrequency ablation of pancreatic insulinoma: a state of the art review. Expet Rev Gastroenterol Hepatol 2024; 18(1–3): 37– 53. DOI: 10.1080/17474124.2024.2321938. 38383965 · DOI
  35. [36]AlKhamisy A Nasani M. A rare case of insulinoma presented with neurological manifestations: a case report. Int J Surg Case Rep 2023; 108: 108397. DOI: 10.1016/j.ijscr.2023.108397. 37327767 PMC10382722 · DOI
  36. [37]Cazabat L Chanson P. Hypoglycémie et insulinome. Annales d’Endocrinologie 2009; 70: S2– S11. DOI: 10.1016/S0003-4266(09)72470-9. 19878764 · DOI
  37. [38]Cougard P Goudet P Peix JL, et al. Les insulinomes dans les néoplasies endocriniennes multiples de type 1 (NEM1). Ann Chir 2000; 125(2): 118– 123. DOI: 10.1016/S0001-4001(00)00112-4. 10998796 · DOI
  38. [39]Ketari-Jamoussi S Debbiche-Chedly A Ben Dhaou B, et al. Un insulinome géant: à propos d’un cas. Ann Endocrinol 2009; 70(1): 71– 75. DOI: 10.1016/j.ando.2008.09.005. 18937931 · DOI
  39. [40]Callender GG Rich TA Perrier ND. Multiple endocrine neoplasia syndromes. Surg Clin 2008; 88(4): 863– 895. DOI: 10.1016/j.suc.2008.05.001. 18672144 · DOI
  40. [41]McAuley G Delaney H Colville J, et al. Multimodality preoperative imaging of pancreatic insulinomas. Clin Radiol 2005; 60(10): 1039– 1050. DOI: 10.1016/j.crad.2005.06.005. 16179163 · DOI
  41. [42]Druce MR Muthuppalaniappan VM O’Leary B, et al. Diagnosis and localisation of insulinoma: the value of modern magnetic resonance imaging in conjunction with calcium stimulation catheterisation. Eur J Endocrinol 2010; 162(5): 971– 978. DOI: 10.1530/EJE-10-0056. 20207727 · DOI
  42. [43]Grover AC Skarulis M Alexander HR, et al. A prospective evaluation of laparoscopic exploration with intraoperative ultrasound as a technique for localizing sporadic insulinomas. Surgery 2005; 138(6): 1003– 1008. DOI: 10.1016/j.surg.2005.09.017. 16360384 · DOI
  43. [44]Sundin A Arnold R Baudin E, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine & hybrid imaging. Neuroendocrinology 2017; 105(3): 212– 244. DOI: 10.1159/000471879. 28355596 · DOI
  44. [45]Azimuddin K Chamberlain RS. The surgical management of pancreatic neuroendocrine tumors. Surg Clin 2001; 81(3): 511– 525. DOI: 10.1016/S0039-6109(05)70140-7. 11459268 · DOI
  45. [46]Masson B Sa-Cunha A Laurent C, et al. Les pancréatectomies laparoscopiques. Ann Chir 2003; 128(7): 452– 456. DOI: 10.1016/S0003-3944(03)00190-1. 14559194 · DOI
  46. [47]Berends FJ Cuesta MA Kazemier G, et al. Laparoscopic detection and resection of insulinomas. Surgery 2000; 128(3): 386– 391. DOI: 10.1067/msy.2000.107413. 10965308 · DOI
  47. [48]Tsang Y Lang BH Shek TW. Assessing the short‐ and long‐term outcomes after resection of benign insulinoma. ANZ J Surg 2016; 86(9): 706– 710. DOI: 10.1111/ans.12891. 25345822 · DOI
  48. [49]Sweet MP Izumisato Y Way LW, et al. Laparoscopic enucleation of insulinomas. Arch Surg 2007; 142(12): 1202– 1204. DOI: 10.1001/archsurg.142.12.1202. 18086988 · DOI
  49. [50]Grant CS. Insulinoma. Best Pract Res Clin Gastroenterol 2005; 19(5): 783– 798. DOI: 10.1016/j.bpg.2005.05.008. 16253900 · DOI
  50. [51]An L Li W Yao KC, et al. Assessment of contrast-enhanced ultrasonography in diagnosis and preoperative localization of insulinoma. Eur J Radiol 2011; 80(3): 675– 680. DOI: 10.1016/j.ejrad.2010.09.014. 20965676 · DOI

Cited by

Sorted by citations

Authors
Bahou, K., Achour, Y., Ilahiane, M., Sekkat, H., Bakali, Y., Mhamdi Alaoui, M., Raiss, M., Sabbah, F., & Hrora, A.
Affiliations
  • Mohammed V University (MA)
  • Digestive Surgical Department C, Ibn Sina University Hospital, Rabat, Morocco
Corresponding author
Bahou, Khawla
ORCID
Venue
Rare Tumors
Publisher
SAGE Publications
Published
2025-01
Volume
17
Pages
20363613241313409-20363613241313409
ISSN
  • 2036-3605 (ISSN-L)
  • 2036-3613
DOI
10.1177/20363613241313409
PMC
PMC11713962
OpenAlex
W4406166269
Cited by
5
References
1
Citations by year
2026: 3 · 2025: 2
FWCI
3.47
Type
journal article
Language
en
Open access
Licence
Locations
  • Rare Tumors (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
  • Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Keywords
pancreatic insulinoma, benign insulinoma, neuroendocrine tumors, hypoglycemia, tumor localization, laparoscopic enucleation, pancreatic surgery, endoscopic ultrasound, radiological imaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review